Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (120)
April 12, 2010
- Maurer's Healthcare Insight (119)
March 1, 2010
- Maurer's Healthcare Insight (118)
January 4, 2010
- Maurer's Healthcare Insight (117)
December 14, 2009
- Maurer's Healthcare Insight (116)
November 30, 2009
- Maurer's Healthcare Insight (115)
November 16, 2009
- Maurer's Healthcare Insight (114)
October 26, 2009
- Maurer's Healthcare Insight (113)
October 5, 2009
- Maurer's Healthcare Insight (112)
September 14, 2009
- Maurer's Healthcare Insight (111)
August 24, 2009
- Maurer's Healthcare Insight (110)
July 27, 2009
- Maurer's Healthcare Insight (109)
June 22, 2009
- Maurer's Healthcare Insight (108)
May 18, 2009
- Maurer's Healthcare Insight (107)
April 27, 2009
- Maurer's Healthcare Insight (106)
March 30, 2009
- Maurer's Healthcare Insight (105)
March 2, 2009
- Maurer's Healthcare Insight (104)
January 26, 2009
- Maurer's Healthcare Insight (103)
January 5, 2009
- Maurer's Healthcare Insight (102)
December 8, 2008
- Maurer's Healthcare Insight (101)
December 1, 2008
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…